Savara presented new data on autoimmune pulmonary alveolar proteinosis (apap) at the american thoracic society (ats) international conference 2024

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the american thoracic society (ats) 2024 international conference that is taking place may 17-22, 2024, in san diego, ca. savara's partner, trillium health llc, presented a poster on the laboratory blood test that was recently developed to aid in the diagnosis of apap. below are summaries of the posters presented: poste.
SVRA Ratings Summary
SVRA Quant Ranking